Evidence map›Paper›PMID 35425776›Full record

ArticleFrontiers in medicine2022

Hyperinflammatory State and Low T1 Adaptive Immune Response in Severe and Critical Acute COVID-19 Patients.

Mercedes Garcia-Gasalla, María Berman-Riu, Jaime Pons, Adrián Rodríguez, Amanda Iglesias, Natalia Martínez-Pomar, Isabel Llompart-Alabern, Melchor Riera, Adrián Ferré Beltrán, Albert Figueras-Castilla and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Mercedes Garcia-GasallaDepartment of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain.
María Berman-RiuBalearic Islands Health Research Institute (IdISBa), Palma, Spain.
Jaime PonsBalearic Islands Health Research Institute (IdISBa), Palma, Spain.
Adrián RodríguezBalearic Islands Health Research Institute (IdISBa), Palma, Spain.
Amanda IglesiasBalearic Islands Health Research Institute (IdISBa), Palma, Spain.
Natalia Martínez-PomarBalearic Islands Health Research Institute (IdISBa), Palma, Spain.
Isabel Llompart-AlabernBalearic Islands Health Research Institute (IdISBa), Palma, Spain.
Melchor RieraDepartment of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain.
Adrián Ferré BeltránDepartment of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain.
Albert Figueras-CastillaIntensive Care Unit, Hospital Universitari Son Espases, Palma, Spain.
Javier MurillasDepartment of Internal Medicine, Hospital Universitari Son Espases, Palma, Spain.
Joana M FerrerBalearic Islands Health Research Institute (IdISBa), Palma, Spain.
Health Research Institute of the Balearic Islands · ESHospital Universitario Son Espases · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A better understanding of COVID-19 immunopathology is needed to identify the most vulnerable patients and improve treatment options. Objective: We aimed to identify immune system cell populations, cytokines, and inflammatory markers related to severity in COVID-19. Methods: 139 hospitalized patients with COVID-19-58 mild/moderate and 81 severe/critical-and 74 recovered patients were included in a prospective longitudinal study. Clinical data and blood samples were obtained on admission for laboratory markers, cytokines, and lymphocyte subsets study. In the recovered patients, lymphocyte subsets were analyzed 8-12 weeks after discharge. Results: A National Early Warning Score 2 >2 (OR:41.4; CI:10.38-167.0), ferritin >583 pg/mL (OR:16.3; CI: 3.88-69.9), neutrophil/lymphocyte ratio >3 (OR: 3.5; CI: 1.08-12.0), sIL-2rα (sCD25) >512 pg/mL (OR: 3.3; CI: 1.48-7.9), IL-1Ra >94 pg/mL (OR: 3.2; IC: 1.4-7.3), and IL-18 >125 pg/mL (OR: 2.4; CI: 1.1-5.0) were associated with severe/critical COVID-19 in the multivariate models used. Lower absolute values of CD3, CD4, CD8, and CD19 lymphocytes together with higher frequencies of NK cells, a CD4 and CD8 activated (CD38+HLA-DR+) memory T cell and effector memory CD45RA+ (EMRA) phenotype, and lower T regulatory cell frequencies were found in severe/critical patients relative to mild/moderate and recovered COVID-19 patients. A significant reduction in Th1, Tfh1, and Tc1 with higher Th2, Tfh2, Tc2, and plasma cell frequencies was found in the most severe cases. Conclusion: A characteristic hyperinflammatory state with significantly elevated neutrophil/lymphocyte ratio and ferritin, IL-1Ra, sIL-2rα, and IL-18 levels together with a "low T1 lymphocyte signature" was found in severe/critical COVID-19 patients.

Indexed as

activated memory T cellCOVID-19 severityEMRA phenotypeIL-18IL-1RasIL-2rαT1 cellsT regulatory cell

Identifiers

PMID35425776
PMCPMC9002349
OpenAlexW4220919126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.